Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The study will conduct with 4 comparative groups orally treated with YHD001 dose level
1(t.i.d.), YHD001 dose level 2(t.i.d.), pelargonium sidoides extract 9mL(t.i.d.) or Placebo
for 7 days.
The treatments will be assigned randomly to patients (n=116) with acute or chronic
bronchitis.